Login to Your Account

CEO: PAH Franchise Still Strong

UTHR Forging Ahead on Oral Treprostinil NDA Despite Miss

By Jennifer Boggs

Thursday, August 25, 2011
Investors of United Therapeutics Corp. experienced a bit of déjà vu Wednesday as shares took a tumble on disappointing data from a Phase III study testing oral treprostinil on top of background therapy in patients with pulmonary arterial hypertension (PAH).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription